Companies ›Healthcare ›1110.HK

1110.HK — HKEX Pharmaceuticals

Kingworld Medicines Group Ltd

HK$0,46

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Kingworld Medicines Group Ltd is a pharmaceutical company engaged in the research, development, production, and sale of generic and branded pharmaceutical products.

Business. Kingworld Medicines Group Ltd (1110.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The company is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 1110.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 1110.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Kingworld Medicines Group Ltd (1110.HK) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The company is headquartered in China and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

Kingworld Medicines Group Ltd has a basic and diluted share count of 622.5 million shares, indicating no immediate dilution pressure from share issuance. However, the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company reported a last actual EPS of 0.07 CNY and a last actual revenue of 1.05 billion CNY. These figures suggest a relatively modest profitability level, though a direct comparison to industry medians is not possible due to the lack of industry-specific metrics in the provided data.

Kingworld Medicines Group Ltd's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or segment concentration risks. The absence of such data limits the ability to evaluate exposure to regional economic or regulatory shifts.

The company's growth trajectory is not clearly defined in the available data, as no forward-looking revenue or earnings estimates are provided. The lack of historical revenue growth data also prevents a detailed analysis of its growth performance.

The company's risk profile is marked by an inability to assess liquidity risk, which could be a concern for investors. The dilution risk is currently low, but the absence of detailed capital structure data means that future dilution potential cannot be ruled out.

No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic or operational direction.

Key takeaways

Kingworld Medicines Group Ltd operates in the Pharmaceuticals industry with a classification confidence of 0.92.
The company has a basic and diluted share count of 622.5 million shares, indicating no immediate dilution pressure.
The company reported a last actual EPS of 0.07 CNY and a last actual revenue of 1.05 billion CNY.
The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
No recent events or forward-looking estimates are available to assess the company's growth trajectory or strategic direction.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2017-03-28

FY 2017 · Full-year highlights

Revenue ¥917.3M, −13,6% YoY; Operating income −29,6% YoY.

Revenue¥917.3M−13,6 % YoY

Operating income¥63.2M−29,6 % YoY

Net income¥11.3M−72,8 % YoY

Free cash flow¥17.1M−49,3 % YoY

EPS—

Operating cash flow¥84.6M−37,7 % YoY

Financials

Income statement

Revenue¥917.3M

Gross profit¥247.9M

Operating income¥63.2M

Net income¥11.3M

Margins

Gross margin27.0%

Operating margin6.9%

Net margin1.2%

FCF margin1.9%

Balance sheet

Total assets¥1.44B

Total liabilities¥824.7M

Total equity¥617.7M

Cash & equivalents¥264.4M

Long-term debt¥433.9M

Cash flow

Operating cash flow¥84.6M

CapEx-¥29.6M

Free cash flow¥17.1M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue ¥917.3M, −13,6% YoY
▍Operating income −29,6% YoY
▍Net income −72,8% YoY
▍Free cash flow −49,3% YoY
▍Net margin 1.2%

Valuation FY

Market price

HK$0,46

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Kingworld Medicines Group Ltd Market data — financials · 2026-05-26
Kingworld Medicines Group Ltd Market data — analyst estimates · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

1110.HKCanonical

HKEX · HKD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2017-03-28 19:48 UTCEARNINGSAnnual results — FY 2017 Revenue CNY 917.3M · Net CNY 11.3M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread